Pharma Mar SAU
BME:PHM
Spain / Healthcare / Biotechnology
Exchange Data
Hide this widget
Price
74.95 EUR
Day change
-0.55 (-0.73%)
52-week range
26.52 - 105.80
16:35 - Closed
Summary of Pharma Mar SAU
Hide this widget
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for th...
Latest Report
27 Feb 2025Next Earnings
24 Apr 2025
Price History
Chart Gallery
Hide this widget
1 Week
1 Month
3 Months
1 Year
5 Year
10 Years
-15.25 (-16.91%)
Data Explorer
Hide this widget
Search metric that you want to observe. Create your own widget, customise and rearrange metrics
| Metric Name | Value | Trend |
|---|---|---|
| Dividend Yield | 0.0% | |
| P/E Ratio | 50.4x | |
| Revenue | 174.9 M | |
| Net Income to Company | 26.125 M |
Peer Benchmarks
Hide this widget
Quote
Value
Size
Growth
Profit
| PHM | Peers | Sector | |
|---|---|---|---|
Market Cap | 1.317 B | 1.171 B | 56.004 M |
Price % of 52 Week High | 70.8% | 79.5% | 60.1% |
Dividend Yield | 0.0% | 0.0% | 0.0% |
Shareholder Yield | 0.3% | 0.8% | -0.7% |
1 Year Price Total Return | 190.6% | 0.4% | -12.6% |
Beta (5 Year) | 0.06 | 0.60 | 0.64 |
In the News
Fair Value
Hide this widget
Average
74.53
Downside
-0.6%
Uncertainty
MED
Spread
39.02 - 136.10
Market Range
52 weeks
€26
€106
€74.95
Analyst Targets
6 analysts
€30
€118
€87.17
Investing Models
€39
€136
€74.53
Financial Health
Health Details
Hide this widget
Financial Health for Pharma Mar is determined by ranking the company on over 100 factors against companies in the Healthcare sector and operating in Developed economic markets.
12345
Good Performance
▼
▼
Financial Models for Pharma Mar SAU
Model Gallery
Hide this widget
| 10Y DCF EBITDA ExitView Updated 16 hours ago |
| 10Y DCF Revenue ExitView Updated 16 hours ago |
| 5Y DCF EBITDA ExitView Updated 16 hours ago |
| 5Y DCF Revenue ExitView Updated 16 hours ago |
| DDM Stable GrowthView Updated 16 hours ago |
| DuPont ROE AnalysisView Updated 4 days ago |
| Earnings Power ValueView Updated 16 hours ago |
| 10Y Historical FinancialsView Updated 4 days ago |
| 5Y Historical FinancialsView Updated 4 days ago |
| EV / EBIT MultiplesView Updated 16 hours ago |
| EV / EBITDA MultiplesView Updated 16 hours ago |
| P/E MultiplesView Updated 16 hours ago |
| Price / Book MultiplesView Updated 16 hours ago |
| Price / Sales MultiplesView Updated 16 hours ago |
| EV / Revenue MultiplesView Updated 16 hours ago |
| CAPM WACC ModelView Updated 22 hours ago |
| 10Y DCF Growth ExitView Updated 16 hours ago |
| 5Y DCF Growth ExitView Updated 16 hours ago |
| DDM Multi StageView Updated 16 hours ago |
Historical Financials
Full Financials
Hide this widget
| (EUR in millions) | Trailing Twelve Months | Fiscal Quarters | |||
|---|---|---|---|---|---|
| Period Ending | Dec-22 | Dec-23 | Dec-24 | Dec-23 | Dec-24 |
| Income Statement | |||||
| Revenue | 196 | 158 | 175 | 41 | 48 |
| Operating Income | 42 | (3.83) | 6.47 | (5.12) | 4.89 |
| Net Profit | 49 | 1.14 | 26 | (6.82) | 19 |
| Diluted EPS | 2.73 | 0.060 | 1.49 | -0.39 | 1.06 |
| EBITDA | 45 | (1.15) | 10 | (4.45) | 7.02 |
| Balance Sheet | |||||
| Cash & ST Invest. | 182 | 163 | 155 | 163 | 155 |
| Current Assets | 275 | 253 | 250 | 253 | 250 |
| Total Assets | 393 | 341 | 350 | 341 | 350 |
| Current Liabilities | 97 | 96 | 83 | 96 | 83 |
| Total Liabilities | 170 | 147 | 141 | 147 | 141 |
| Total Equity | 223 | 193 | 208 | 193 | 208 |
| Total Debt | 43 | 44 | 51 | 44 | 51 |
| Cash Flow Statement | |||||
| Cash Flow Operations | 38 | (13) | 6.03 | (2.69) | 1.69 |
| Cash From Investing | 11 | (43) | 1.03 | 1.66 | 20 |
| Cash From Financing | (13) | (32) | (5.35) | (6.32) | 4.21 |
| Free Cash Flow | 29 | (28) | (8.99) | (7.24) | 0.29 |
Analyst Notes
April 19, 2025
Hide this widget